Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Positron emission tomography imaging for lymphoma.

Guy Jerusalem1, Roland Hustinx, Yves Beguin

  • 1Division of Hemato-Oncology, Department of Medicine, Medical Oncology CHU, University of Liège, Sart Tilman B35, B-4000 Liège, Belgium. g.jerusalem@chu.ulg.ac.be

Current Opinion in Oncology
|August 12, 2005
PubMed
Summary

Fluorodeoxyglucose positron emission tomography (FDG-PET) is crucial for diagnosing and managing lymphoma, offering valuable prognostic information and superior imaging compared to older methods. Routine use in lymphoma patients is recommended.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.

Cell reports·2026
Same author

Multimodal PET/CT-based PD-L1 status prediction in lung cancer via semi-supervised and unsupervised deep learning.

Scientific reports·2026
Same author

Role of [<sup>18</sup>F]FDG PET/CT in the monitoring and management of abdominal aortic aneurysms.

Acta cardiologica·2026
Same author

Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies.

Journal of experimental & clinical cancer research : CR·2026
Same author

A phase 2 study of abemaciclib in patients with brain metastases secondary to non-small cell lung cancer or melanoma.

Neuro-oncology advances·2026
Same author

Coping with checkpoint inhibitor adverse events: Assisting cancer patients in skills development - insights from the Immuno'Act© pre-experimental pilot study.

Patient education and counseling·2026

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiology

Background:

  • Fluorodeoxyglucose positron emission tomography (FDG-PET) has emerged as a significant tool in oncological imaging.
  • Its role in lymphoma management has evolved, particularly with advancements since 2004.

Purpose of the Study:

  • To review the current applications and limitations of FDG-PET in lymphoma management.
  • To focus on studies published from January 2004 onwards.

Main Methods:

  • Review of published literature on FDG-PET in lymphoma.
  • Analysis of studies comparing FDG-PET with conventional staging and other imaging modalities.

Main Results:

  • FDG-PET is recommended at initial diagnosis for Hodgkin's disease, enhancing conventional staging.

Related Experiment Videos

  • Residual FDG-PET uptake post-chemotherapy is a prognostic indicator, though not yet a basis for treatment change.
  • FDG-PET/CT is superior to separate interpretations and Ga scintigraphy, aiding radiation therapy and biopsy planning.
  • Concerns exist regarding the positive predictive value of FDG-PET post-treatment, especially in pediatric lymphoma.

    • Conclusions:

    • FDG-PET is the leading nuclear medicine imaging modality for lymphoma.
    • Routine utilization of FDG-PET in the treatment of lymphoma patients is advocated.